3D Printing Market Gets Pharma Regulatory Boost in France

MB Therapeutics Secures French ANSM Authorization for 3D Printed Pharmaceutical Cartridges 

MONTPELLIER, France October 5, 2026 MB Therapeutics, a pharmaceutical 3D printing start-up headquartered in Montpellier, France, has received pharmaceutical establishment authorization from the French National Agency for Medicines and Health Products Safety (ANSM) to manufacture semi-solid pharmaceutical cartridges used in the 3D printing of solid oral dosage forms  a development that underscores the accelerating regulatory acceptance of additive manufacturing in the healthcare sector and signals a pivotal moment for the global 3D Printing Market, which was valued at USD 20.51 billion in 2023 and is projected to reach USD 83.13 billion by 2030, at a CAGR of 20.6%. 

The ANSM authorization confirms compliance of MB Therapeutics' quality management system and manufacturing facilities with the agency's requirements for pharmaceutical manufacturer status. Operational compliance with Good Manufacturing Practices (GMP) at the facility was still ongoing ahead of its official commercial launch.

Each cartridge is described by MB Therapeutics as a patented, airtight container prefilled in a GMP environment with a homogeneous pharmaceutical paste containing an active pharmaceutical ingredient (API) and selected excipients. The cartridges are designed exclusively for MB Therapeutics' 3D printers, which are intended to equip hospital pharmacies to produce oral dosage forms at the precise dose required by each individual patient.

The company's model ensures full quality and traceability from cartridge production through to point-of-care printing within hospital settings. MB Therapeutics has been collaborating with Nimes University Hospital (CHU de Nîmes) for more than a decade, developing formulations specifically adapted for pediatric and geriatric patients populations historically underserved by standardized pharmaceutical dosage systems.

"Beyond precise dose adjustment and rapid availability in hospital pharmacies, 3D printing allows us to offer adapted galenic forms, such as personalized dispersible and orodispersible dosage forms," said Dr. Manon Perez, Pharmacist and Quality Director at MB Therapeutics. 

Key Highlights: 

• Regulatory Milestone: MB Therapeutics has received ANSM pharmaceutical establishment authorization a formal recognition of its GMP-compliant manufacturing infrastructure for 3D printed pharmaceutical cartridges. 

• Point-of-Care Personalization: The company's 3D printing system is designed to be deployed directly within hospital pharmacies, enabling on-demand production of patient-specific oral dosage forms. 

• Underserved Patient Populations: The technology directly addresses unmet clinical needs in pediatric and geriatric care, where standardized dosages frequently fail to meet individual therapeutic requirements. 

• Funding & Partnerships: MB Therapeutics secured a €2 million funding round in 2025 and has maintained a decade-long clinical collaboration with Nimes University Hospital, reinforcing the credibility of its development pipeline. 

Analyst Insight: 

According to analysts at Next Move Strategy Consulting, the ANSM authorization granted to MB Therapeutics represents a meaningful inflection point for pharmaceutical additive manufacturing in Europe. Regulatory approvals of this nature are critical catalysts for broader institutional adoption, as hospital procurement decisions are heavily contingent on demonstrated compliance with national medicines agencies. NMSC analysts note that the healthcare vertical remains one of the most strategically significant growth segments within the global additive manufacturing market, driven by rising demand for patient-specific implants, prosthetics, and now, personalized oral dosage forms. As regulatory frameworks across the EU and beyond begin to accommodate 3D printed pharmaceuticals, the addressable market for point-of-care manufacturing solutions is expected to expand substantially through the forecast period to 2030. 

Industry Outlook: 

The ANSM authorization for MB Therapeutics arrives at a time when the global additive manufacturing sector is undergoing a structural shift from prototyping and industrial tooling toward regulated, end-use production in high-stakes sectors such as healthcare. The pharmaceutical 3D printing segment, in particular, is gaining traction as hospital systems seek to reduce dependency on centralized drug manufacturing and improve responsiveness to individual patient needs.

The MB Therapeutics model combining GMP-certified cartridge production with hospital-based 3D printing offers a scalable framework that could be replicated across European healthcare systems and beyond. As national medicines agencies in other jurisdictions develop analogous regulatory pathways, similar authorizations are likely to follow, further legitimizing additive manufacturing as a viable modality for pharmaceutical production. The broader 3D printing market's projected trajectory toward USD 83.13 billion by 2030 reflects precisely this kind of cross-sector regulatory and commercial maturation. 

Source: VoxelMatters

For More Information: Download FREE Sample on 3D Printing Market Report

Prepared By: Sanyukta Deb